Cardiol Therapeutics
CRDL
35 hedge funds and large institutions have $5.78M invested in Cardiol Therapeutics in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 6 closing their positions.
400% more call options, than puts
Call options by funds: $5K | Put options by funds: $1K
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
6% more funds holding
Funds holding: 33 → 35 (+2)
0.58% less ownership
Funds ownership: 10.45% → 9.86% (-0.58%)
3% less capital invested
Capital invested by funds: $5.97M → $5.78M (-$190K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
Tejara Capital
London,
United Kingdom
|
+$142K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$47.8K |
| 3 |
LNWTC
Laird Norton Wetherby Trust Company
Seattle,
Washington
|
+$36.9K |
| 4 |
FIA
FNY Investment Advisers
New York
|
+$31.8K |
| 5 |
MA
MONECO Advisors
Fairfield,
Connecticut
|
+$13.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AXS Investments
Port Chester,
New York
|
-$502K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$32.6K |
| 3 |
N
Natixis
Paris,
France
|
-$22.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$15.8K |
| 5 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$13.3K |
CRDL Hedge Fund Activity: Q3 2023 in Review
35 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q3 2023, worth a combined $5.78M — down 3.2% from $5.97M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CRDL positions and 6 closed out — a net gain of 2 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was Tejara Capital, adding an estimated $142K. The largest seller was AXS Investments, cutting an estimated $502K.
- 35 institutional investors held Cardiol Therapeutics (CRDL) as of Q3 2023, up from 33 in Q2 2023.
- Funds reported $5.78M of Cardiol Therapeutics stock for Q3 2023, down 3.2% quarter-over-quarter.
- 8 funds opened new Cardiol Therapeutics positions in Q3 2023 and 6 closed out, a net change of +2 holders.
- The largest Cardiol Therapeutics buyer in Q3 2023 was Tejara Capital, an estimated $142K added.
- The largest Cardiol Therapeutics seller in Q3 2023 was AXS Investments, an estimated $502K sold.
Based on aggregated 13F filings for Q3 2023.